A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

By Tarun Sai Lomte A small but carefully monitored 20-week study reveals that semaglutide delivers weight loss in older ...

By Deena Beasley and Julie Steenhuysen SAN DIEGO, Dec 3 (Reuters) - Details from two large trials of Novo Nordisk's GLP-1 ...

Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose ...

There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.

The authors conclude that early use of semaglutide may serve as an effective adjunctive strategy to mitigate the metabolic ...

Oral semaglutide did not significantly reduce disease progression in patients with early Alzheimer disease, according to results from two phase 3 trials.

The most common side effects of GLP-1 medicines are related to digestion: nausea, vomiting, diarrhoea, indigestion, stomach ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

By Deena Beasley SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in ...